Also, in patients with unresectable hepatocellular carcinoma, anti-PD-L1 in combination with anti-VEGF demonstrated improved PFS and OS compared to sorafenib (median PFS, 6.8 months versus 4.3 months; and OS at 1 year, 67.2% versus 54.6%) (44). The gene discussed is CD274; the disease is hepatocellular carcinoma.